Promising biotech setup here, had a nice break of 70 recently and may be looking to go higher. Potentially risky if XBI rolls over but strong momentum here nonetheless. Good luck traders!
*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team entered $MIRM on 5/28/21 at $16.30 per share. Today we're...
The london area and some countries are ordering millions of body bags. They are super bearish. At the bottom. As usual. Covid is over. There were 2 deadly waves and there won't be a third. I hope I'm not offending anyone too much. I know that to big brains going against the fear narrative - which changes everyday - makes you a conspiracy theorist that believes...
A staple of Cathie Wood's ARKK Invest fund, Teladoc looks to be winding up for a big move in the coming days after breaking the resistance of a supply line that has kept TDOC stagnant since the peak of its small rally in June. Now we find it at a key support level just outside of the trendline and finding support on our 21 MA as well. I am long on TDOC with a stop...
I did a small research yesterday and also published a full article on the website. Doximity will go public on NYSE and is an online network for doctors. It is an early-stage company that is already profitable which is something unusual for companies at this stage. Also, Clover is not a profitable company yet. I believe is worth looking at the full article. Just...
*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* My team has been following clinical-stage biotech company $LCTX for the past...
The algorithmic advisor Market Miracle is suggesting for some days a LONG entry on the title CENTENE $CNC The company that is basically a Healthcare is in charge of the US-wide care of patients with and without health coverage. The signals that I have been provided on Centene these days did not have a particularly explosive aspect for which for my fault they...
The Healthcare sector, Utilities sector, and Transportation sector - here represented by the S&P Health Care Index (S5HLTH, in blue), Dow Jones Utility Average ( DJU, in purple), and the Dow Jones Transportation Average (DTX, in orange) - do not usually act as early indicators against the broader market (here represented by the DJIA in gray, and the NASDAQ in...
The Healthcare sector and Utilities sector - here represented by the S&P Health Care Index (S5HLTH, in blue) and Dow Jones Utility Average (DJU, in purple) - do not usually act as early indicators against the broader market (here represented by the DJIA in gray, and the NASDAQ in black)... except perhaps for DJU falling from a peak in Jan 2015, and in Dec 2017.
Dow (DJIA) - NASDAQ (IXIC) divergence since June 7, sectoral study PART 1. Consumer Staples tracking the DJI downwards.
-Nabriva Therapeutics (NASDAQ:NBRV) and Sinovant Sciences' antibiotic lefamulin was non-inferior to moxifloxacin in a phase 3 study, according to top-line results. -In a modified intent to treat (mITT) population, the clinical response success rates were 76.8% for lefamulin and 71.4% for moxifloxacin. -Also, Sinovant inked an agreement with a Chinese subsidiary...
CLOV short term classic bearish divergence on the 4H.... market is shit for small caps and spac's rn... where will this lead us past support?
Large Southwestern Health System Signs New Contract for Streamline Health® eValuator™ $STRM today announced it has signed a contract with a 1,300-bed, Epic EMR-based health system in Arizona. The healthcare provider will use eValuator’s cloud-based automated pre- and post-bill coding analysis technology to help improve revenue integrity for their inpatient and...
Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan® today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. The pivotal study will evaluate safety and performance of C-Scan as well as subject...
Exela Technologies Wins $90 Million Contract for Cloud-Hosted PCH Global, Delivering Healthcare Solutions for Major US Insurer $XELA today announced a 10 year, $90 million venture blending automation technologies, SaaS, and services through its PCH Global platform, which officially launched in September of last year. This effort will accelerate the digital...
Corporate Profile DaVita is a Fortune 500® health care provider focused on transforming care delivery to improve quality of life for patients around the globe. The company is the largest provider of kidney care services in the U.S. and has been a leader in clinical quality and innovation for 20 years. Through DaVita Kidney Care, the company treats patients with...
So far I'm trying to find a channel in which #EYES is traveling. Currently I think that it should start retesting the previous "supports" We shall see.... 1. Weed/EV 2. Healthcare 3.Technology
COHERUS BIOSCIENCES Inc., NASDAQ:CHRS , is a bioscience company that has not yet not benefited from the sector's outperformance despite significantly improving financials and the business becoming profitable. When the stock price cracks the $21 level it will unlock a significant bullish potential.